



Final Appraisal Recommendation
Advice No: 1421 –September 2021

Etravirine (Intelence®) 25 mg, 100 mg, 200 mg tablets

Submission by Janssen-Cilag Ltd

Recommendation of AWMSG

Etravirine (Intelence®) is recommended as an option for use within NHS Wales, in combination with a boosted protease inhibitor and other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adults and in antiretroviral treatment-experienced paediatric patients from 2 years of age.

Additional note(s):

- This advice incorporates and replaces the AWMSG recommendation for etravirine (Intelence®) for use in combination with a boosted protease inhibitor and other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced paediatric patients from 6 years to less than 18 years of age (advice number 3213, originally published December 2013) and the AWMSG recommendation for etravirine (Intelence®) for the treatment of HIV-1 infected, antiretroviral treatment-experienced adults in combination with a boosted protease inhibitor and other antiretroviral medicinal products (advice number 0609, originally published September 2009).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference numbers 4506, 1683 and 140), which includes the All Wales Therapeutics and Toxicology Centre (AWTTC) assessment, AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1421:
Etravirine (Intelence®) 25 mg, 100 mg, 200 mg tablets. September 2021.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendations. Accreditation is valid for 5 years from October 2016. More information on accreditation can be viewed at <http://www.nice.org.uk/about/what-we-do/accreditation>